Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives
Abstract
In recent times, permeation of nanotechnology to modern medicine has revolutionized transformation, especially in the case of cancer diagnosis and therapy, positioning nanomedicine as a key pillar of next-generation healthcare. Tuning the physicochemical properties of nanoparticles such as size, morphology, and surface charge, enables controlled targeted drug delivery, increased cellular uptake and controlled therapeutic release. Nanomedicine-based platforms can improve certain drawbacks associated with conventional therapies including poor aqueous solubility, unfavorable pharmacokinetics, systemic toxicity and low bioavailability for specific therapeutic agents. While consistent tumor-specific accumulation, intratumoral heterogeneity, drug resistance, and long-term therapeutic outcomes remains challenging and highly formulation- and patient-dependent. This review paper besides, focussing on individual nanocarrier classes or specific therapeutic modalities, also provide an integrated and critical perspective on next-generation nanomedicine by connecting nanocarrier design with tumor-specific accumulation, intracellular trafficking, stimuli-responsive drug release, combination therapy and clinical translation. Recent advances in polymeric, lipid-based, inorganic, biological, and hybrid nanocarriers are systematically discussed, with particular stress on surface engineering, ligand-mediated targeting, multifunctional delivery systems and nanoengineered cancer medicine. The potential of these platforms for elevating therapeutic precision, overcoming biological barriers, multidrug resistance and enabling site-specific delivery is critically studied. In addition, major translational challenges, including large-scale fabrication, reproducibility, long-term safety, regulatory barriers, and nanotoxicological concerns are also addressed. Finally, emerging directions involving personalized nanomedicine, combination therapies, and artificial intelligence-assisted nanoparticle design are highlighted to provide perspectives toward safer, more effective, and patient-concentrated cancer therapy.